- Home
- TLPH vs NEUP Comparison
TLPH vs NEUP Comparison
Compare TLPH & NEUP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TLPH
- NEUP
- Stock Information
- Founded
- TLPH 2005
- NEUP 1996
- Country
- TLPH United States
- NEUP United States
- Employees
- TLPH N/A
- NEUP N/A
- Industry
- TLPH Biotechnology: Pharmaceutical Preparations
- NEUP
- Sector
- TLPH Health Care
- NEUP
- Exchange
- TLPH Nasdaq
- NEUP Nasdaq
- Market Cap
- TLPH 10.6M
- NEUP 12.7M
- IPO Year
- TLPH 2011
- NEUP N/A
- Fundamental
- Price
- TLPH $0.45
- NEUP $7.13
- Analyst Decision
- TLPH Strong Buy
- NEUP Strong Buy
- Analyst Count
- TLPH 1
- NEUP 1
- Target Price
- TLPH $6.00
- NEUP $21.00
- AVG Volume (30 Days)
- TLPH 42.9K
- NEUP 26.7K
- Earning Date
- TLPH 08-13-2025
- NEUP 08-15-2025
- Dividend Yield
- TLPH N/A
- NEUP N/A
- EPS Growth
- TLPH N/A
- NEUP N/A
- EPS
- TLPH N/A
- NEUP 0.00
- Revenue
- TLPH $27,000.00
- NEUP $15,662,715.00
- Revenue This Year
- TLPH N/A
- NEUP N/A
- Revenue Next Year
- TLPH $14,533.26
- NEUP N/A
- P/E Ratio
- TLPH N/A
- NEUP $2.30
- Revenue Growth
- TLPH N/A
- NEUP N/A
- 52 Week Low
- TLPH $0.43
- NEUP $2.90
- 52 Week High
- TLPH $1.19
- NEUP $126.00
- Technical
- Relative Strength Index (RSI)
- TLPH 45.62
- NEUP N/A
- Support Level
- TLPH $0.45
- NEUP N/A
- Resistance Level
- TLPH $0.52
- NEUP N/A
- Average True Range (ATR)
- TLPH 0.03
- NEUP 0.00
- MACD
- TLPH -0.00
- NEUP 0.00
- Stochastic Oscillator
- TLPH 35.33
- NEUP 0.00
About TLPH Talphera Inc.
Talphera Inc. is a pharmaceutical company focused on the development and commercialization of therapies for use in medically supervised settings. The Company's nafamostat product candidates include Niyad and LTX-608. Its portfolio consists of nafamostat product candidates and pre-filled syringe product candidates.
About NEUP Neuphoria Therapeutics Inc. Common Stock
Neuphoria Therapeutics Inc is a clinical stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company is advancing its drug candidate, BNC 210, an oral, proprietary, selective negative allosteric modulator of the Alpha7 nicotinic acetylcholine receptor, for the acute treatment of social anxiety disorder and for chronic treatment of post-traumatic stress disorder.